Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379765 | 0.91 | NPSR1 (0.54) | NPSR1RAB9ALMNAALDH1A1CYP1A2 | |
| SCHEMBL3379143 | 0.90 | NPSR1 (0.44) | NPSR1RAB9ALMNAL3MBTL1ALDH1A1 | |
| SCHEMBL13102007 | 0.85 | HDAC6 (0.43) | NPSR1LMNAALDH1A1MEN1HTT | |
| SCHEMBL13282992 | 0.85 | NPSR1 (0.45) | NPSR1RAB9AMAPK14LMNAUSP2 | |
| SCHEMBL3379725 | 0.84 | NPSR1 (0.57) | NPSR1RAB9AMAPK14LMNAUSP2 | |
| SCHEMBL3378807 | 0.84 | NPSR1 (0.57) | NPSR1RAB9ALMNAUSP2L3MBTL1 | |
| SCHEMBL13101623 | 0.82 | SMN1; SMN2 (0.52) | RAB9ALMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3379749 | 0.81 | NPSR1 (0.54) | NPSR1RAB9ALMNAALDH1A1CYP1A2 | |
| SCHEMBL3376843 | 0.81 | NPSR1 (0.53) | NPSR1RAB9ALMNAUSP2L3MBTL1 | |
| SCHEMBL13102209 | 0.80 | TRPV1 (0.39) | NPSR1LMNAUSP2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585522-B1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100190746-A1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| EP-1585522-A4 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1585522-A2 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040198724-A1 | Quinazolinones as potassium channel modulators | ICAGEN, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004058704-A2 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198724-A1 | Quinazolinones as potassium channel modulators | KCNQ1, KCNK17, KCNQ2 | NPSR1 1722/4885RAB9A 560/4885MAPK14 1542/4885 |
| US-20100190746-A1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNK17, KCNQ2 | NPSR1 1722/4885RAB9A 560/4885MAPK14 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.